We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $125.83 · 12 analysts
Stored first · Google News · Yahoo Finance (English)
Dianthus Therapeutics (DNTH) CFO sells 31,249 shares in 10b5-1 trades - Stock Titan
Dianthus Therapeutics (DNTH) CFO sells 31,249 shares in 10b5-1 trades Stock Titan
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing - Stock Titan
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 05. | After market close (AMC) | $-0.91 | — | — | $248.75K | — | Scheduled |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-1.73 | — | — | $4.91M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.99 | — | — | $2.74M | Reported |
| FY2025 Q1 | 2024. 03. 31. | Time TBD | — | $-0.54 | — | — | $874K | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 06. | Wedbush | — | Maintain | Outperform → Outperform | — | Wedbush: Outperform |
| 2026. 04. 10. | Wolfe Research | — | Initiate coverage | — → Outperform | — | Wolfe Research: Outperform |
| 2026. 03. 19. | Wells Fargo | — | Initiate coverage | — → Overweight | — | Wells Fargo: Overweight |
| 2026. 03. 13. | Wedbush | — | Maintain | Outperform → Outperform | — | Wedbush: Outperform |
| 2026. 03. 10. | Wedbush | — | Maintain | Outperform → Outperform | — | Wedbush: Outperform |
| 2026. 03. 10. | Raymond James | — | Upgrade | Outperform → Strong Buy | — | Raymond James: Outperform → Strong Buy |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.